Related Experiment Video
Updated: May 19, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
Drug-induced valvular heart disease
Bernard Cosyns1, Steven Droogmans, Raphael Rosenhek
1Department of Cardiology, UZ Brussel, Brussels, Belgium. bcosyns@gmail.com
Drug-induced valvular heart disease (DIVHD) can result from various medications, including those for Parkinson's and migraine. Early recognition of clinical and echocardiographic risk factors is crucial for managing this potentially severe condition, even after drug cessation.
Area of Science:
- Cardiology
- Pharmacology
- Toxicology
Background:
- Drug-induced valvular heart disease (DIVHD) has been recognized since the 1960s.
- Associations include ergot derivatives, anorectic drugs, Parkinson's treatments, and endocrine disease medications.
- More recent associations involve 3,4-methylendioxymetamphetamine (MDMA) and benfluorex.
Purpose of the Study:
- To review the associations between various drugs and valvular heart disease (VHD).
- To highlight the potential for long-term implications of DIVHD, even after drug cessation.
- To emphasize the importance of early recognition and management of DIVHD.
Main Methods:
- Literature review of reported cases and associations of drug-induced valvular heart disease.
- Analysis of clinical and echocardiographic findings in patients with DIVHD.
- Discussion of historical and recent drug associations with VHD.
Main Results:
- DIVHD is associated with a range of medications, including those used for migraine, weight loss, Parkinson's disease, and hyperprolactinemia.
- MDMA and benfluorex are identified as more recent drug associations with DIVHD.
- Patients may require valve surgery years after discontinuing the causative agent, indicating persistent effects.
Conclusions:
- DIVHD is not infrequent, can be severe, and is linked to multiple drugs.
- Long-term consequences of DIVHD can persist even after drug cessation.
- Careful evaluation of clinical and echocardiographic risk factors is essential for early recognition and timely management of DIVHD.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Mitral Stenosis I: Introduction
Mitral Regurgitation I: Introduction
Cardiovascular Drugs: Classification based on Therapeutic Indications
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy II: Dilated Cardiomyopathy

